Related Experiment Video

Updated: Apr 3, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.7K

Combined Therapies for Lysosomal Storage Diseases

M Gabig-Cimińska, J Jakóbkiewicz-Banecka, M Malinowska

  • 1Department of Molecular Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdańsk, Poland. grzegorz.wegrzyn@biol.ug.edu.pl.

Current Molecular Medicine
|September 23, 2015
PubMed

Insights

Combination therapies show promise for treating complex lysosomal storage diseases (LSDs). Research reviews current approaches, suggesting combined treatments may overcome limitations of single therapies for LSD patients.

Area of Science:

  • Biochemistry
  • Genetics
  • Molecular Medicine

Background:

  • Lysosomal storage diseases (LSDs) are a group of over 50 genetic disorders.
  • These diseases result from lysosomal protein dysfunction, leading to compound accumulation.
  • Current treatments face challenges, especially for central nervous system and skeletal manifestations.

Purpose of the Study:

  • To review and discuss the current status of combination therapies for LSDs.
  • To evaluate the effectiveness of combining different therapeutic approaches for LSDs.
  • To highlight the potential of combination strategies based on published data.

Main Methods:

  • Literature review of existing studies on LSD combination therapies.
  • Analysis of published data on the efficacy and limitations of various treatment combinations.
  • Discussion of the molecular basis and clinical outcomes of combined therapeutic strategies.

Main Results:

  • No single therapeutic approach effectively corrects all LSD symptoms.
  • Combination therapies are emerging as a potential strategy to address complex LSD manifestations.
  • Published data suggests that combining treatments may offer improved outcomes for LSD patients.

Conclusions:

  • Lysosomal storage diseases require multifaceted treatment strategies.
  • Combination therapies hold significant potential for improving the management of LSDs.
  • Further research into combined therapeutic approaches is crucial for advancing LSD treatment.

More Related Videos

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

8.6K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

684

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.8K
Lysosomes01:31

Lysosomes

Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
27.1K
Lysosomes01:31

Lysosomes

3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
620